Lung Hydatid CystEchinococcusisNCT06281522
The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus)
An observational study of Lung Hydatid Cyst, run by Abdullah Adiyaman at 1 site in Turkey (Türkiye).
Trial summary
This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index… Read more about this study
- Who is it for?
- Ages 18 to 83 years
- Conditions the study is for
- Lung Hydatid Cyst
- What is being tested?
- Operated patients with hydatid cyst of the lung
- How many people
- 54 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 18 Dec 2023to 30 Jun 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 83 years
- All sexes
- Adult, Older adult
Study population: Peripheral blood results of patients hospitalized in the thoracic surgery clinic of S.B.Ü Van Training and Research Hospital due to hydatid cyst of the lung (surgery) will be evaluated.
Who may be able to join
- Between January 1, 2022 - December 1, 2023, patients with hydatid cyst of the lung who were hospitalized in the Thoracic Surgery Service
Who cannot join
- Between January 1, 2022 and December 1, 2023, other patients admitted to the Thoracic Surgery Service
Trial locations and contacts
1 site in 1 country.
Suleyman Gokalp Gunes contact
Turkey (Türkiye)1 site, 1 recruiting
- Recruiting
University of Health Sciences, Van Training and Research Hospital
Van
About this study
This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.
Read the detailed description
Hydatid cyst of the lung (HCC) is a health problem caused by a small species of tapeworm called Echinococcus granulosus, a parasitic infection that can occur in humans and other mammals. Hydatid cysts are cysts caused by the larvae of the parasite. They most commonly form in the liver and lungs, but can also occur in other organs. E. granulosus lives in the intestines of animals and excretes them in their feces. Humans can get the eggs of this parasite through contact or under poor hygiene conditions. The ingested eggs hatch in the stomach and intestine and the larvae enter the bloodstream, then form cysts in various organs throughout the body.
Cystic echinococcosis is a disease in which a large group of patients live in conditions of material and social poverty. The disease has a widespread distribution worldwide and the regions with high disease prevalence are Southeast Europe, the Middle East, North, Central and East Asia and South America.
- Conditions
- Lung Hydatid Cyst
- Being tested
- Operated patients with hydatid cyst of the lung
- Keywords
- Lung Hydatid Cyst, neutrophils,, lymphocytes,, platelets
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Operated patients with hydatid cyst of the lungOther
Also called File screening and blood test results will be evaluated
File screening and blood test results will be evaluated
What is being measured
The primary outcome is the main question the study is designed to answer.
Calculation of laboratory markers
euzonophil (10^9/L) , neutrophil (10^9/L), lymphocyte (10^9/L), platelet (10^3/uL) counts and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic immune inflammatory index (SII = P × N/L) values calculated using these data in the peripheral blood results of patients diagnosed with pulmonary hydatid cyst (PHC) in the pre-operative period and post-operative 3rd month will be examined retrospectively.
Measured: 2 monts
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Feb 2024
- Study start18 Dec 2023
- Primary completion30 Mar 2024 (estimated)
- Study completion30 Jun 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung Hydatid CystStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Abdullah Adiyaman
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Abdullah Adiyaman, Yuzuncu Yil University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06281522
- Sponsor's protocol ID
- University of Health Sciences
- Acronym
- Echinococcusis
- Status last verified
- Feb 2024
- First submitted
- 14 Jan 2024
- Last updated
- 28 Feb 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Feb 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Importance of Inflammatory Markers Calculated From Preoperative and Postoperative Peripheral Blood Results in the Diagnosis and Treatment of Patients Operated for Hydatid Cyst of the Lung (Lung Echinococcus Granulosus)
- ClinicalTrials.gov ID
- NCT06281522
- Acronym / sponsor ID
- Echinococcusis / University of Health Sciences
- Conditions
- Lung Hydatid Cyst
- Keywords
- Lung Hydatid Cyst, neutrophils,, lymphocytes,, platelets
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Abdullah AdiyamanUniversity, hospital or other
- Study start
- 18 Dec 2023 (actual)
- Primary completion
- 30 Mar 2024 (estimated)
- Study completion
- 30 Jun 2024 (estimated)
- First posted
- 28 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate the role of these laboratory findings in the differential diagnosis and management of pulmonary hydatid cyst (PHC) by examining the number of euzonophils, neutrophils, lymphocytes, platelets and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and systemic immune inflammatory index values in the peripheral blood of patients diagnosed with pulmonary hydatid cyst (PHC) in the preoperative period and post-operative 3rd month. Although we have extensive data on hydatid liver cysts, there is limited information in the literature on the laboratory values of patients with PHC. This study aims to provide more scientific basis for the diagnosis and management of PHC and is considered as an inexpensive, reproducible and easily calculable method to improve the accurate diagnosis and management of AKH in clinical practice.
Detailed description
Hydatid cyst of the lung (HCC) is a health problem caused by a small species of tapeworm called Echinococcus granulosus, a parasitic infection that can occur in humans and other mammals. Hydatid cysts are cysts caused by the larvae of the parasite. They most commonly form in the liver and lungs, but can also occur in other organs. E. granulosus lives in the intestines of animals and excretes them in their feces. Humans can get the eggs of this parasite through contact or under poor hygiene conditions. The ingested eggs hatch in the stomach and intestine and the larvae enter the bloodstream, then form cysts in various organs throughout the body.
Cystic echinococcosis is a disease in which a large group of patients live in conditions of material and social poverty. The disease has a widespread distribution worldwide and the regions with high disease prevalence are Southeast Europe, the Middle East, North, Central and East Asia and South America.
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 83 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Peripheral blood results of patients hospitalized in the thoracic surgery clinic of S.B.Ü Van Training and Research Hospital due to hydatid cyst of the lung (surgery) will be evaluated.
Key inclusion criteria (1 listed)
- Between January 1, 2022 - December 1, 2023, patients with hydatid cyst of the lung who were hospitalized in the Thoracic Surgery Service
Key exclusion criteria (1 listed)
- Between January 1, 2022 and December 1, 2023, other patients admitted to the Thoracic Surgery Service
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Operated patients with hydatid cyst of the lungAlso: File screening and blood test results will be evaluatedFile screening and blood test results will be evaluated | Other | – |
Primary outcome
Calculation of laboratory markers
Time frame: 2 monts
euzonophil (10^9/L) , neutrophil (10^9/L), lymphocyte (10^9/L), platelet (10^3/uL) counts and neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, systemic immune inflammatory index (SII = P × N/L) values calculated using these data in the peripheral blood results of patients diagnosed with pulmonary hydatid cyst (PHC) in the pre-operative period and post-operative 3rd month will be examined retrospectively.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Feb 2024.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Suleyman Gokalp Gunes contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Hydatid Cyst, run by Abdullah Adiyaman at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 28 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Abdullah ADIYAMAN (+905465880056, aadyaman@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Calculation of laboratory markers (time frame: 2 monts). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Feb 2024.